-
For cancer patients who have exhausted all available treatment options, Phase I research trials of new oncology drugs may be their only hope. But does that hope come at too high a price?
-
-
-
-
To provide you with critical information on the updated regulations from the Centers for Medicare and Medicaid Services, Thomson American Health Consultants offers "New EMTALA Regulations: Are They Too Good to be True?" an audio conference on Tuesday, Oct. 21, 2:30-3:30 p.m. ET.
-
"EMTALA: The Essential Guide to Compliance" from Thomson American Health Consultants, publisher of ED Legal Letter and Hospital Risk Management, explains how the changes to EMTALA will affect emergency departments and off-campus clinics. In-depth articles, at-a-glance tables, and Q-and-A discussions of real-life situations are presented, and key differences between the old EMTALA and the new changes are succinctly explained.
-
Historically, ED Legal Letter has evaluated the mistakes of physicians after the fact. The diagnosis has been missed, the case has been litigated and decided. The benefit of hindsight provides an essential learning and risk management opportunity for the reader. This months issue will evaluate the thinking and behavior of physicians that lead to errors in diagnosis. An analysis of the cognitive errors in the ED by physicians will provide reflection on future premature or inaccurate diagnosis in the ED. This issue will allow physicians to recognize that certain types of thinking and behavior can be harmful to the patient. Acknowledging these faults will reduce bad outcomes and prevent future litigation.
-
-
Question: Should an IRB have a conflict of interest (COI) policy? If so, what should be in it?
-
As long as local protocols continue to enroll subjects and collect data, they must submit to annual reviews by the institutional review board. But what happens once the study concludes, enrollment is closed, and all data are collected? What obligation does the IRB have to continue monitoring the study?